KRAZATI (adagrasib) tablets, for oral use Initial U.S. Approval: 2022
Krazati is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) whose tumor has an abnormal KRAS G12C gene. Krazati works as a targeted therapy designed to attack the mutated KRAS protein to suppress tumor growth.
Brand Name: | KRAZATI |
Generic Name: | adagrasib |
Strength: | Recommended dosage: • 600 mg orally twice daily. • Swallow tablets whole with or without food. |
Manufacturer: | Mirati Therapeutics, Inc. |
Approved By: | EMA, USFDA |
Source Details: Patient Information
IPN, New Delhi can facilitate patient to import of “KRAZATI (adagrasib) tablets” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for KRAZATI (adagrasib) tablets price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.